![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
SAN FRANCISCO, Sept. 16, 2022 (GLOBE NEWSWIRE) — AltruBio Inc. (“AltruBio” or “the Company”), a scientific stage biotech firm devoted to the improvement of novel therapeutics for the remedy of immunological ailments with excessive unmet medical wants, right now introduced that AltruBio President and CEO Dr. Judy Chou will converse on “The Next Wave of Targeted Therapies” at the Longwood Healthcare Leaders Fall Webconference on Wednesday, September 21, 2022.
Details about the presentation are as follows:
Session: THE NEXT WAVE OF TARGETED THERAPIES
Presenter: Judy Chou, Ph.D., President and CEO
Date: Wednesday, September 21, 2022
Time: 10:40 a.m. ET
Registration: Here
About Longwood Healthcare Leaders:
Longwood Healthcare Leaders conferences carry collectively main biotech and pharma CEOs, heads of R&D, prime teachers, and healthcare buyers for off-the-record discussions to drive transparency and collaboration so as to speed up the translation of discoveries into medicines to assist sufferers. Substantial donations enabled by these conferences profit a number of charities.
To be taught extra about the occasion, view the agenda, and request an invite, go to www.longwoodhealthcareleaders.com.
Meetings are invitation-only. To request an invite or advocate a colleague, e-mail [email protected].
About AltruBio Inc.
AltruBio is a privately held biotechnology firm headquartered in San Francisco that’s targeted on growing novel therapeutics for the remedy of immunological ailments with excessive unmet medical wants. The firm has leveraged its deep understanding of the function PSGL-1 performs as an immune checkpoint regulator protein to develop a platform for T-cell mediated immunological ailments. Its first-generation molecule, neihulizumab (ALTB-168), an immune checkpoint agonist antibody focusing on PSGL-1/CD162 has achieved proof of mechanism in 4 autoimmune and inflammatory ailments together with ulcerative colitis, steroid refractory acute graft-versus-host illness (SR-aGVHD), psoriatic arthritis, and psoriasis. The next-generation PSGL-1 agonist ALTB-268 is a tetravalent model of ALTB-168 and has demonstrated excessive efficiency through the similar mechanism, which makes it appropriate for subcutaneous administration in the confirmed indications and is advancing towards IND for a number of autoimmune and inflammatory issues.
Note on Forward-Looking Statements
Statements made on this information launch that aren’t historic information are forward-looking statements inside the that means of the Private Securities Litigation Reform Act of 1995. Words corresponding to expects, believes, intends, and comparable expressions are meant to establish forward-looking statements. Actual outcomes might differ materially from these projected in any forward-looking assertion. Specifically, there are a variety of essential components that would trigger precise outcomes to differ materially from these anticipated, corresponding to the Company’s potential to elevate further capital, and dangers associated to the Company’s potential to provoke, and enroll sufferers in, deliberate scientific trials. You mustn’t place undue reliance on any forward-looking statements. The Company assumes no obligation to replace any forward-looking statements because of new info, future occasions or developments, besides as required by regulation.
Contacts
AltruBio Inc:
+1-415-655-6603
+886-2-2627-2707
[email protected]
Media Contact:
Darren Opland, PhD
LifeSci Communications
+1-646-627-8387
[email protected]
